Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr;35(4):1219.
doi: 10.1038/s41375-021-01187-4. Epub 2021 Feb 25.

Response to: Ruxolitinib withdrawal due to the COVID-19

Tiziano Barbui  1 , Alessandra Carobbio  2
Affiliations
Comment

Response to: Ruxolitinib withdrawal due to the COVID-19

Tiziano Barbui et al. Leukemia. 2021 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Comment on

  • High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib.
    Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A. Barbui T, et al. Leukemia. 2021 Feb;35(2):485-493. doi: 10.1038/s41375-020-01107-y. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414483 Free PMC article.
  • Ruxolitinib withdrawal due to the COVID-19.
    Lucijanic M, Kusec R. Lucijanic M, et al. Leukemia. 2021 Apr;35(4):1218. doi: 10.1038/s41375-021-01214-4. Epub 2021 Mar 17. Leukemia. 2021. PMID: 33731851 Free PMC article. No abstract available.

References

    1. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021. 10.1038/s41375-020-01107-y. - PMC - PubMed
    1. Richiardi L, Bellocco R, Zugna D. Mediation analysis in epidemiology: methods, interpretation and bias. Int J Epidemiol. 2013;42:1511–9. doi: 10.1093/ije/dyt127. - DOI - PubMed